Research Discipline(s): Basic, Translational
Primary Title:
Additional Titles & Affiliations:
RESEARCH TOPICS
Glioblastoma, Medulloblastoma
Max Rady College of Medicine
401 Brodie-727 McDermot Ave
Winnipeg, MB R3E 3P5
Canada
Understanding and challenging the brain cancer by finding better therapeutic options
Research Summary
Dr. Tanveer Sharif’s current research is focused on identifying and characterizing new metabolism-based precision medicine therapeutic strategies for treating aggressive brain tumors. His work focuses on the two most common types of brain cancers in children and adults, medulloblastoma (MB) and glioblastoma (GBM). Using relevant cell and animal models as well as patient-derived brain tumor samples, Dr. Sharif’s research takes an in-depth approach to investigate the molecular mechanisms that mediate metabolic vulnerabilities and tumor heterogeneity to identify new therapeutic targets to improve patient responses and outcomes.
Goals
- Understanding and targeting the role of metabolic rewiring and metabolic plasticity within heterogeneous brain tumor populations.
- Understanding the metabolic regulation of tumor suppressors and oncogenes
- Target metabolism-mediated modulation of post-translational modifications and epigenetics in brain cancer.
- Find cancer cells specific metabolism based therapeutic interventions to target brain cancer.
Research Biography
Dr. Tanveer Sharif is a pharmacist turned researcher, he received his BSc in Pharmacy and MSc in Pharmacology. Dr. Sharif completed his PhD at the University of Strasbourg in France before moving to Canada in 2013 to pursue his postdoctoral fellowship at Dalhousie University. At Dalhousie, Dr. Sharif studied the role of tumor suppressors and metabolism in embryonal carcinoma stem cells and patient-derived brain tumor-initiating cells. In 2019, Dr. Sharif joined UM as a principal investigator to lead a new tumor suppressor biology and Metabolism program in the department of pathology. His research focuses to understand and target the metabolic adaptations and their role in glioblastoma and medulloblastoma.
Achievements
- Grant award, Canadian Institute of Health Research (2022-2027, $956,250). Role: Principal Applicant.
- John R. Evans Leaders Fund grant, Canadian Foundation for Innovation & University of Manitoba (2022, $821,862). Role: Co-Principal Applicant.
- Discovery Launch Supplement grant, Natural Sciences and Engineering Council of Canada (2021-22, $125,000). Role: Principal Applicant.
- Discovery grant, Natural Sciences and Engineering Council of Canada (2021-2026, $150,000). Role: Principal Applicant.
- Grant award, Canadian Cancer Society (2021-2026, $600,000). Role: Principal Applicant.
- Grant award, Cancer Research Society (2021-2023, $120,000). Role: Principal Applicant.
- Grant award, Health Sciences Centre Foundation (2020-2022, $70,000)Role: Principal Applicant.
- Grant award, Manitoba Medical Service Foundation and Cancer Care Manitoba Foundation (2021, $31,000). Role: Principal Applicant.
- Recipients of the 2022 ICR Early Career Investigator in Cancer Award. The Early Career Investigator in Cancer Award recognizes the excellence of research conducted in Canada and is presented to the new investigators who submitted the highest-ranking grants from the Fall competition of the Project Scheme.
-
Featured Publications
- Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. May 2023. Nature Communications 14(1). DOI: 10.1038/s41467-023-38049-9
- Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations. July 2023Acta Neuropathologica Communications 11(1).
- ACETYL-AMANTADINE AS A DIAGNOSTIC BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. August 2022Neuro-Oncology Advances 4(Supplement_1):i2-i2
